HEPPENHEIM & BERLIN, GERMANY – There is currently no globally approved drug for the treatment of sudden hearing loss, a condition that affects thousands of individuals each year. However, AudioCure Pharma, a Berlin-based biopharmaceutical company, is advancing research on AC102, an innovative drug candidate that has shown promising results in preclinical and Phase 1 clinical studies.
In a significant development, InfectoPharm, a Heppenheim-based pharmaceutical company specializing in ear, nose, and throat (ENT) treatments, has joined as a key partner in AudioCure’s latest round of financing. InfectoPharm now strengthens an existing group of investors, which includes main investor MED-EL and seed investor High-Tech Gründerfonds (HTGF).
The collaboration aims to advance the clinical development of AC102, currently being evaluated in a Europe-wide Phase 2 study for its effectiveness in treating sudden hearing loss.
Investors in the current financing round with AudioCure Management. From left to right: Philipp Zöller (CEO InfectoPharm), Prof Hans Rommelspacher (founder AudioCure), Dr Reimar Schlingensiepen (CEO AudioCure), Dr Ingeborg Hochmair (CEO MED-EL) and Dr Christian Kannemeier (Senior Investment Manager HTGF). Image credit: AudioCure.
Strategic Collaboration and Industry Expertise
The investors are providing both financial support and scientific expertise to drive the development of new treatments for hearing loss. MED-EL Medical Electronics and InfectoPharm Arzneimittel bring decades of experience in the ENT sector, offering insights that extend beyond funding.
“AudioCure and its partners complement each other perfectly. Together, we can advance our research and development activities even further and develop innovative active ingredients. We are also pleased to now have InfectoPharm’s many years of experience in the pharmaceutical industry on board
–Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma
Advancing Clinical Research on AC102
The additional investment will primarily support the continued development of AC102, which has already demonstrated tolerability and safety in human trials. In preclinical models of hearing loss, AC102 showed the potential to restore hearing almost completely, surpassing the efficacy of conventional corticosteroid treatment.
“As a specialist in pharmaceutical products for ear, nose, and throat conditions, we are very familiar with the difficult situation of sudden hearing loss patients,” said Philipp Zöller, Managing Partner of InfectoPharm Arzneimittel und Consilium GmbH. “We are therefore delighted to be able to support the development of a potentially groundbreaking drug like AC102, both financially and with our expertise, as part of the AudioCure investor team.”
About AudioCure Pharma
AudioCure Pharma is a Berlin-based biopharmaceutical company focused on developing innovative treatments for hearing loss and related auditory conditions. The company’s research aims to provide effective therapeutic solutions for patients suffering from sudden hearing loss and neurodegenerative auditory disorders.
About InfectoPharm
InfectoPharm Arzneimittel und Consilium GmbH is a Germany-based pharmaceutical company specializing in ear, nose, and throat treatments. With more than 30 years of experience, InfectoPharm focuses on developing and delivering targeted therapeutic solutions in various medical fields.
Source: AudioCure
